2021 | Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE | Mamounas E. P.; Untch M.; Mano M. S.; CHIUN-SHENG HUANG ; Geyer C. E.; von Minckwitz G.; Wolmark N.; Pivot X.; Kuemmel S.; DiGiovanna M.P.; Kaufman B.; Kunz G.; Conlin A.K.; Alcedo J.C.; Kuehn T.; Wapnir I.; Fontana A.; Hackmann J.; Polikoff J.; Saghatchian M.; Brufsky A.; Yang Y.; Zimovjanova M.; Boulet T.; Liu H.; Tesarowski D.; Lam L.H.; Song C.; Smitt M.; Loibl S. | Annals of oncology : official journal of the European Society for Medical Oncology | 57 | 49 | |